SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-029066
Filing Date
2023-06-21
Accepted
2023-06-21 07:53:19
Documents
13
Period of Report
2023-06-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eypt-20230620.htm   iXBRL 8-K 167481
2 EX-10.1 eypt-ex10_1.htm EX-10.1 154915
  Complete submission text file 0000950170-23-029066.txt   463042

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eypt-20230620.xsd EX-101.SCH 2475
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eypt-20230620_lab.xml EX-101.LAB 12806
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eypt-20230620_pre.xml EX-101.PRE 9457
7 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20230620_htm.xml XML 4523
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 231027421
SIC: 3826 Laboratory Analytical Instruments
Industrial Applications and Services